Trial
NCT04331665
Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia
UnknownTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University Health Network, Toronto
Collaborators
—
Condition
COVID-19
Intervention
Ruxolitinib
Why stopped
A Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint. With this news, recruitment was stopped for this study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-19